Company Description
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally.
The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis.
In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension.
Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases.
The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
| Country | United States |
| Founded | 1999 |
| IPO Date | Aug 11, 2009 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 91 |
| CEO | A. Kazimi |
Contact Details
Address: 1600 West End Avenue, Suite 1300 Nashville, Tennessee 37203 United States | |
| Phone | 615 255 0068 |
| Website | cumberlandpharma.com |
Stock Details
| Ticker Symbol | CPIX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001087294 |
| CUSIP Number | 230770109 |
| ISIN Number | US2307701092 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| A. J. Kazimi MBA | Founder, Chairman, President and Chief Executive Officer |
| John Michael Hamm | Vice President and Chief Financial Officer |
| James Lowrance Herman | Executive Vice President of National Accounts and Chief Compliance Officer |
| Chris T. Bitterman | Vice President of Sales and Marketing |
| Todd M. Anthony | Vice President of Organizational Development |
| Jean W. Marstiller | Senior Vice President of Administrative Services and Corporate Secretary |
| Adam S. Mostafa | Managing Director |
| Erin Smith Gull | Senior Corporate Relations Associate |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 4, 2024 | 8-K | Current Report |
| Aug 9, 2024 | 10-Q | Quarterly Report |
| Aug 6, 2024 | 8-K | Current Report |
| May 10, 2024 | 10-Q | Quarterly Report |
| May 7, 2024 | 8-K | Current Report |
| Apr 29, 2024 | 8-K | Current Report |
| Mar 22, 2024 | ARS | Filing |
| Mar 20, 2024 | 8-K | Current Report |
| Mar 20, 2024 | 424B5 | Filing |
| Mar 13, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |